Abstract
Introduction/background: Generic substitution of antiepileptic medicines, especially of modified release products, is discussed controversially. All the more in Germany, since rebate contracts between pharmaceutical manufacturers and statutory health insurance (SHI) funds associated with compulsory[for full text, please go to the a.m. URL]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
